Home » Stocks » Mersana Therapeutics

Mersana Therapeutics, Inc. (MRSN)

Stock Price: $18.60 USD 0.71 (3.97%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $18.70 +0.10 (0.54%) Oct 22, 4:08 PM

Stock Price Chart

Key Info

Market Cap 1.27B
Revenue (ttm) 1.69M
Net Income (ttm) -69.75M
Shares Out 68.42M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $18.60
Previous Close $17.89
Change ($) 0.71
Change (%) 3.97%
Day's Open 17.92
Day's Range 17.85 - 18.79
Day's Volume 1,605,756
52-Week Range 1.32 - 26.64

More Stats

Market Cap 1.27B
Enterprise Value 998.24M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 68.42M
Float 57.30M
EPS (basic) -1.40
EPS (diluted) -1.37
FCF / Share -1.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.69M
Short Ratio 4.40
Short % of Float 11.68%
Beta 2.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 751.64
PB Ratio 4.47
Revenue 1.69M
Operating Income -70.82M
Net Income -69.75M
Free Cash Flow -66.16M
Net Cash 274.28M
Net Cash / Share 4.01
Gross Margin -762.97%
Operating Margin -4,183.34%
Profit Margin -4,119.90%
FCF Margin -3,907.74%
ROA -19.68%
ROE -36.51%
ROIC -213.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(44.09% upside)
Current: $18.60
Target: 26.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth297.61%-39.62%-30.3%142.99%-
Gross Profit42.1210.5917.5525.1710.36
Operating Income-30.20-65.66-39.62-13.82-16.34
Net Income-28.21-64.26-38.71-13.70-16.43
Shares Outstanding43.4923.0312.021.271.22
Earnings Per Share-0.65-2.79-3.22-10.82-13.43
Operating Cash Flow-67.74-55.22-42.6831.59-9.64
Capital Expenditures-0.61-1.37-1.14-1.08-0.62
Free Cash Flow-68.35-56.59-43.8230.50-10.26
Cash & Equivalents99.7970.1311510011.53
Total Debt7.76----
Net Cash / Debt92.0370.1311510011.53
Book Value78.328.8069.99-55.62-42.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mersana Therapeutics, Inc.
Country United States
Employees 83
CEO Anna Protopapas

Stock Information

Ticker Symbol MRSN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRSN
IPO Date June 28, 2017


Mersana Therapeutics, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.